Abcam, ab259160, Human STK35 knockout HEK-293T cell lysate

Size: 1Kit
STK35 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-STK35, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
STK35 also known as Serine/Threonine Kinase 35 or New Kinase 4 (NIK4) is a protein with a mass of approximately 55 kDa. This protein functions as a serine/threonine kinase involved in the phosphorylation of target substrates an activity essential for regulating various cellular processes. STK35 is widely expressed in several tissues with notable expression in the heart lung and skeletal muscles suggesting broad involvement in physiological regulation.
Biological function summary
The function of STK35 extends to roles in cell proliferation and migration. It has been shown to act in the regulation of the cytoskeleton contributing to cellular architecture and dynamics. STK35 often forms part of protein complexes that modulate other kinases and structural proteins thereby influencing cellular behavior. These interactions emphasize its role in maintaining cellular function and integrity.
Pathways
STK35 plays a significant role in signaling pathways such as the PI3K/Akt pathway and the MAPK/ERK pathway. The involvement in these pathways links STK35 to cell survival growth and metabolism. Through these interactions STK35 aligns with critical signaling proteins like Akt and ERK coordinating cellular responses to a variety of stimuli and ensuring appropriate cellular activities.
Research has demonstrated a connection between STK35 and various forms of cancer including lung and breast cancer. STK35 involvement in cancer is often associated with its influence on cell proliferation and migration. Additionally STK35's interaction with other oncogenic proteins such as Akt further implicates its role in tumorigenesis and tumor progression making it a potential target for therapeutic intervention in cancer treatments.